keramatrix® is an absorbable matrix rich in keratin protein that delivers Replicine™ Functional Keratin® as it dissolves into the wound. Due to the unique biological function of keratin protein, keramatrix® delivers a level performance typically associated with high cost biological dressings, in a much lower cost and much more convenient format.

Indications

keramatrix® is designed for full and partial thickness wounds with low to high exudate, such as:

  • Venous leg ulcers
  • Arterial ulcers
  • Diabetic ulcers
  • Pressure ulcers
  • Skin graft donor sites
  • First and second degree burns
  • Superficial injuries, cuts, abrasions and surgical wounds

Improved healing

keramatrix® has demonstrated faster epithelisation rates and more robust skin after healing in numerous clinical studies. In vitro studies have shown that Replicine™ Functional Keratin® increases the rates of proliferation and migration of keratinocyte cells, specifically encouraging keratinocyte cells into a active healing phase earlier than when keramatrix is not used. This means keramatrix® can speed healing, improve the healed outcome and reduce cost of care in the following treatment areas:

Chronic wound care

keramatrix® was a treatment option in a 22 patient case series of long duration mixed etiology venous leg ulcers. 73% of nurses and 82% of patients indicated a preference for keramatrix® over conventional therapy and 71% of large (>5cm2), long duration (>6 months) wound healed compared to a historical expectation of 13% for this wound type.

  • C Hammond, M Than, J Walker. From the laboratory to the leg: Patient's and nurses perceptions of product application using three different dressing formats, Wound Practice and Research, 18, 4, 189-195, November 2010.
  • C Vivas, A D Maderal, M P Than, R S Kirsner, .Letter: Designing clinical trials to bring wound products to market. Int Wound J. 2011 Dec 14. doi: 10.1111/j.1742-481X.2011.00907.x
  • M P Than, R A Smith, C Hammond, R Kelly, C Marsh, A D Maderal, R S Kirsner. Keratin-based Wound Care Products for Treatment of Resistant Vascular Wounds. J Clin Aesthet Dermatol. 2012 Dec;5(12):31-5.http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3533319/

keramatrix® was a treatment option in a 45 wound case series of mixed etiology chronic wounds, including venous leg ulcers and diabetic wounds. 87% of hard to heal wounds (>2 month duration) achieved a significant 76-100% reduction in wound area.

Burn treatment

Faster epithelisation rates lead to faster wound closure and so reduced infection rates and a better healed outcome, including potentially less severe scarring and pigmentation effects. An 80 patient cohort study on partial thickness and superficial burns, compared burn management using keratin wound care with standard of care in the treatment facility. Burn patients, with an age range of 7 months to 69 years, had wounds treated with either keragelT®, keragel® or keramatrix® depending on location and exudate level of the wound. The keratin products were found to facilitate healing faster (mean healing time of 8.7 days compared to 14.4 days) with minimal permanent skin change or scarring reported for the treatment group. The keratin products were well tolerated with minimal pain and itch, a common issue at dressing change. The keratin treatments were easy to use and administer for the health professionals in both outpatients and community settings and a cost of care analysis showed a 47% cost saving compared to the control group.

Donor site treatment

A randomized, blinded, controlled study of 26 split skin graft donor site wounds showed a statistically significant improvement in epithelisation rate for use of keramatrix compared to standard care control. Improved healing rate lead to an estimated 2 day improvement in healing time and associated reduction in risk of infection, hypertrophic scarring and other complications.

  • A Davidson, N Jina, C Marsh, M Than and J Symcock, Do Functional Keratin Dressings Accelerate Epithelialization in Human Partial Thickness Wounds? A Randomized Controlled Trial on Skin Graft Donor Sites eplasty13e45 aug 2013. http://www.medscape.com/viewarticle/810610_2

Skin tears

keramatrix® was a treatment option in a 20 patient clinical case series of skin tears in a community setting. Carers using keramatrix® consistently reported faster healing rates, stronger and more robust skin and improved cosmetic appearance of the healed wound relative to standard care for this wound type.

  • J Redmond, E Milner, C Marsh, A case study series using keratin based technology for skin tears, Proceedings of SAWC 2012, Atlanta, GA, April 2012

Reduced cost of care

Using keramatrix® Improves healing outcomes, reduces total cost of care and improves quality of life. Faster healing of chronic wounds leads to 47% reduction in total care cost. Contact us to find out how.

Usage

keramatrix® provides a high level of biological performance but is a shelf stable, simple to use product packaged in a sterile 4inx4in (10cmx10cm) convenience. Application can range from daily to weekly, depending on wound type. For more details on usage download these guidelines and instructions for use for keramatrix®.

How to get keramatrix®

keramatrix® is approved for use and distributed throughout many of the major regions of the world. 

Click here to find out how best to access keramatrix®.